Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karen Harrington-Brock is active.

Publication


Featured researches published by Karen Harrington-Brock.


Mutation Research | 1989

Micronucleus, chromosome aberration, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells☆

Carolyn L. Doerr; Karen Harrington-Brock; Martha M. Moore

In testing the hypothesis that the small-colony thymidine kinase-deficient mutants of L5178Y/TK+/- -3.7.2C mouse lymphoma cells represent an estimate of the clastogenicity of test chemicals, we have been performing gross aberration analysis. The present study was initiated to determine if the cytokinesis block method of micronucleus analysis could be performed in mouse lymphoma cells and to compare 3 different endpoints of clastogenicity: the number of metaphases with aberrations, number of binucleates with micronuclei, and small-colony TK mutant frequency. In this study, 12 compounds having varying clastogenic potencies were evaluated. As would be expected, the 3 endpoints vary in the relative magnitude of the quantitated response. This difference likely results from the types of clastogenic damage detected by each endpoint. Of the 3 endpoints tested, only the small-colony TK mutant frequency measures events compatible with long-term cell survival.


Mutation Research Letters | 1992

Large deletions are tolerated at the hprt locus of in vivo derived human T-lymphocytes

James C. Fuscoe; Lisa J. Zimmerman; Karen Harrington-Brock; Martha M. Moore

A cloning assay was used to recover hprt- T-lymphocytes from adult human males. Analysis of crude cellular extracts by polymerase chain reactions (PCRs) demonstrated that 7% (16/218) of the hprt mutations were due to total deletion of the hprt gene. 14 of the 16 mutants were examined by PCR for the presence of flanking DNA to determine the extent of the deletions. The deletion mutation in 13 mutants was at least 350 kb with 5 of these deletions being at least 700 kb. The largest deletions were greater than 15 times the size of the hprt gene. Therefore, large deletions are tolerated at the hprt locus of human T-lymphocytes.


Environmental and Molecular Mutagenesis | 2000

Mouse Lymphoma thymidine kinase locus gene mutation assay : International Workshop on Genotoxicity Test Procedures Workgroup Report

Martha M. Moore; Masamitsu Honma; Julie Clements; Takumi Awogi; George Bolcsfoldi; Jane Cole; B. Bhaskar Gollapudi; Karen Harrington-Brock; Ann D. Mitchell; Wolfgang Muster; Brian Myhr; Michael R. O'Donovan; Marie-Claude Ouldelhkim; Richard H.C. San; Hiroyasu Shimada; Leon F. Stankowski

The Mouse Lymphoma Assay (MLA) Workgroup addressed and reached consensus on a number of issues. Discussion focused on five areas: (1) acceptable assay versions; (2) cytotoxicity measure; (3) 24‐hr treatment; (4) microwell colony counting and sizing; and (5) data acceptability/statistical analysis. Although the International Conference on Harmonisation (ICH) indicated a preference for the microwell over the soft agar method, all of the workgroup members agreed that both versions of the MLA are equally acceptable. The workgroup agreed that it is desirable for both assay versions to use the same measure of cytotoxicity to define the acceptable and required concentration range. Currently, laboratories using the microwell version use the relative survival (RS) determined by cloning immediately after the treatment. Laboratories using the soft agar method do not obtain an RS but use the relative total growth (RTG), a combination of the relative suspension growth (RSG) during the expression period and the relative cloning efficiency determined at the time of mutant selection. The workgroup agreed to investigate the RSG, the RS, and the RTG and to develop further guidance. In the interim, the workgroup reached consensus that the RTG be used as the standard measure of cytotoxicity. The ICH recommended a 24‐hr treatment in the absence of S9 when negative results are obtained with short (3–4 hr) treatments. The workgroup agreed to retain this requirement but acknowledged that more data are needed prior to making final recommendations concerning the need for and the specific protocol for the 24‐hr treatment. Environ. Mol. Mutagen. 35:185–190, 2000 Published 2000 Wiley‐Liss, Inc.


Mutation Research Letters | 1993

Genotoxicity of three pyridine compounds to L5178Y mouse lymphoma cells

Kerry L. Dearfield; Karen Harrington-Brock; Carolyn L. Doerr; Lisa Parker; Martha M. Moore

The L5178Y mouse lymphoma assay was used to examine the potential mutagenicity of three halogenated pyridine compounds. Position effects of the halogen moiety and the role of metabolic activation were analyzed based on induced mutant frequency, gross chromosome aberrations, and micronuclei. Without activation, 2-chloropyridine, 3-chloropyridine, and 2-chloro-5-trifluoromethylpyridine produced a small increase in mutant frequency; only the 2-chloropyridine activity was significantly increased with activation. All three compounds were also clastogenic as demonstrated by increases in chromosome aberrations and micronuclei (except for 2-chloro-5-trifluoromethylpyridine which did not induce micronuclei either with or without activation).


Mutation Research\/environmental Mutagenesis and Related Subjects | 1991

Genotoxicity of 2-amino-6-N-hydroxyadenine (AHA) to mouse lymphoma and CHO cells.

Martha M. Moore; Karen Harrington-Brock; Lisa Parker; Carolyn L. Doerr; John C. Hozier

2-Amino-6-N-hydroxyadenine (AHA) treated L5178Y/TK (+/-)-3.7.2C mouse lymphoma cells were evaluated for mutations at the tk, hgprt, and Na+/K+ ATPase loci, as well as for gross chromosome aberrations and induction of micronuclei. In addition, AHA was evaluated for its ability to induce HGPRT mutants in CHO cells. AHA was found to induce mutations at all evaluated loci and in both cell types. The TK mutants were primarily large colonies although a few small colonies were also induced, particularly at the higher concentrations. Preliminary cytogenetic analysis of AHA-treated mouse lymphoma cells indicated that some gross aberrations but not micronuclei were induced. The 20 small-colony TK mutants evaluated by banded karyotype indicate that only a small fraction (2 of 20) showed chromosome 11 abnormalities. From these studies, it appears that AHA may be one of a very few chemicals that is capable of inducing multi-locus point mutations, with only slight clastogenic activity. Particularly at the higher concentrations, some of the mutants may contain multi-locus point mutations that result in slow growth.


Environmental and Molecular Mutagenesis | 2003

Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: Induction of chromosomal mutations but not gene mutations

Andrew D. Kligerman; Carolyn L. Doerr; Alan H. Tennant; Karen Harrington-Brock; James W. Allen; Ernest Winkfield; Patricia Poorman-Allen; Bijit Kundu; Kunihiro Funasaka; Barbara C. Roop; Marc J. Mass; David M. DeMarini


Mutagenesis | 1989

Differential mutant quantitation at the mouse lymphoma tk and CHO hgprt loci.

Martha M. Moore; Karen Harrington-Brock; Carolyn L. Doerr; Kerry L. Dearfield


Environmental and Molecular Mutagenesis | 2002

Mouse lymphoma thymidine kinase gene mutation assay: Follow‐up International Workshop on Genotoxicity Test Procedures, New Orleans, Louisiana, April 2000

Martha M. Moore; Masamitsu Honma; Julie Clements; Karen Harrington-Brock; Takumi Awogi; George Bolcsfoldi; Maria Cifone; Deborah D. Collard; Michael Fellows; Kathryn Flanders; B. Bhaskar Gollapudi; Peter Jenkinson; Paul Kirby; Stephan Kirchner; Joann Kraycer; Stephen McEnaney; Wolfgang Muster; Brian Myhr; Michael O'Donovan; Jo Oliver; Marie‐Claude Ouldelhkim; Kamala Pant; Robert Preston; Colin Riach; Richard H.C. San; Hiroyasu Shimada; Leon F. Stankowski


Mutagenesis | 1990

Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro

Lorraine C. Backer; James W. Allen; Karen Harrington-Brock; James Campbell; David M. DeMarini; Carolyn L. Doerr; Deborah R. Howard; Andrew D. Kligerman; Martha M. Moore


Environmental Health Perspectives | 2000

Mutagenicity of trichloroethylene and its metabolites: implications for the risk assessment of trichloroethylene.

Martha M. Moore; Karen Harrington-Brock

Collaboration


Dive into the Karen Harrington-Brock's collaboration.

Top Co-Authors

Avatar

Martha M. Moore

United States Environmental Protection Agency

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kerry L. Dearfield

United States Environmental Protection Agency

View shared research outputs
Top Co-Authors

Avatar

James C. Fuscoe

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Lisa Parker

Research Triangle Park

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew D. Kligerman

United States Environmental Protection Agency

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David M. DeMarini

United States Environmental Protection Agency

View shared research outputs
Researchain Logo
Decentralizing Knowledge